5M96

Synthesis and biological evaluation of new triazolo and imidazolopyridine RORgt inverse agonists


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.77 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.192 

wwPDB Validation 3D Report Full Report


This is version 2.0 of the entry. See complete history

Literature

Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine ROR gamma t Inverse Agonists.

Hintermann, S.Guntermann, C.Mattes, H.Carcache, D.A.Wagner, J.Vulpetti, A.Billich, A.Dawson, J.Kaupmann, K.Kallen, J.Stringer, R.Orain, D.

(2016) ChemMedChem 11: 2640-2648

  • DOI: 10.1002/cmdc.201600500

  • PubMed Abstract: 
  • Retinoic-acid-related orphan receptor γt (RORγt) is a key transcription factor implicated in the production of pro-inflammatory Th17 cytokines, which drive a number of autoimmune diseases. Despite diverse chemical series having been reported, combini ...

    Retinoic-acid-related orphan receptor γt (RORγt) is a key transcription factor implicated in the production of pro-inflammatory Th17 cytokines, which drive a number of autoimmune diseases. Despite diverse chemical series having been reported, combining high potency with a good physicochemical profile has been a very challenging task in the RORγt inhibitor field. Based on available chemical structures and incorporating in-house knowledge, a new series of triazolo- and imidazopyridine RORγt inverse agonists was designed. In addition, replacement of the terminal cyclopentylamide metabolic soft spot by five-membered heterocycles was investigated. From our efforts, we identified an optimal 6,7,8-substituted imidazo[1,2-a]pyridine core system and a 5-tert-butyl-1,2,4-oxadiazole as cyclopentylamide replacement leading to compounds 10 ((S)-N-(8-((4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl)methyl)-7-methylimidazo[1,2-a]pyridin-6-yl)-2-methylpyrimidine-5-carboxamide) and 33 ((S)-N-(8-((4-(5-(tert-butyl)-1,2,4-oxadiazol-3-yl)-3-methylpiperazin-1-yl)methyl)-7-methylimidazo[1,2-a]pyridin-6-yl)-2-methylpyrimidine-5-carboxamide). Both derivatives showed good pharmacological potencies in biochemical and cell-based assays combined with excellent physicochemical properties, including low to medium plasma protein binding across species. Finally, 10 and 33 were shown to be active in a rodent pharmacokinetic/pharmacodynamic (PK/PD) model after oral gavage at 15 mg kg -1 , lowering IL-17 cytokine production in ex vivo antigen recall assays.


    Organizational Affiliation

    CPC, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.,ATI, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.,Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.,MAP, Novartis Institutes for BioMedical Research, Novartis Campus, 4002, Basel, Switzerland.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Nuclear receptor ROR-gamma
A, B
230Homo sapiensMutation(s): 1 
Gene Names: RORC (NR1F3, RORG, RZRG)
Find proteins for P51449 (Homo sapiens)
Go to Gene View: RORC
Go to UniProtKB:  P51449
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
Q6Y
Query on Q6Y

Download SDF File 
Download CCD File 
A, B
~{N}-[8-[[(3~{S})-4-cyclopentylcarbonyl-3-methyl-piperazin-1-yl]methyl]-7-methyl-imidazo[1,2-a]pyridin-6-yl]-2-methyl-pyrimidine-5-carboxamide
C26 H33 N7 O2
GMRCLEMCHGYDSY-KRWDZBQOSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.77 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.192 
  • Space Group: P 61
Unit Cell:
Length (Å)Angle (°)
a = 100.017α = 90.00
b = 100.017β = 90.00
c = 115.686γ = 120.00
Software Package:
Software NamePurpose
PHASERphasing
REFMACrefinement
XSCALEdata scaling
PDB_EXTRACTdata extraction
XSCALEdata scaling
XSCALEdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2016-10-31 
  • Released Date: 2016-12-14 
  • Deposition Author(s): Kallen, J.

Revision History 

  • Version 1.0: 2016-12-14
    Type: Initial release
  • Version 1.1: 2016-12-28
    Type: Database references
  • Version 2.0: 2018-12-19
    Type: Atomic model, Data collection, Derived calculations